Clemens, Andreas 1966-
Andreas Clemens
VIAF ID: 424145857069122921626 (Personal)
Permalink: http://viaf.org/viaf/424145857069122921626
Preferred Forms
- 100 0 _ ‡a Andreas Clemens
- 100 1 _ ‡a Clemens, Andreas ‡d 1966-
4xx's: Alternate Name Forms (4)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
Application of machine learning methods to bridge the gap between non-interventional studies and randomized controlled trials in ophthalmic patients with neovascular age-related macular degeneration | |
Brolucizumab 12- and 16-week fixed dosing potential in neovascular AMD : a post hoc evaluation of data from the HAWK and HARRIER trials | |
Clinical impact and healthcare resource utilization associated with early versus late COPD diagnosis in patients from UK CPRD database | |
Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial | |
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice | |
Dabigatranetexilat, ein neuer oraler direkter Thrombininhibitor klinische Entwicklung | |
Does real-time artificial intelligence-based visual pathology enhancement of three-dimensional optical coherence tomography scans optimise treatment decision in patients with nAMD? Rationale and design of the RAZORBILL study | |
Dose-response analysis of ranibizumab as-needed regimens for visual improvement in patients with diabetic macular edema using a modelling approach | |
Efficacy and safety of brolucizumab in age‐related macular degeneration: a systematic review of real‐world studies | |
Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations | |
THE GLOBAL REGISTRY PROGRAM ON LONG-TERM ORAL ANTI-THROMBOTIC TREATMENT IN PATIENTS WITH ATRIAL FIBRILLATION (GLORIA-AF): FIRST ASSESSMENT OF BASELINE CHARACTERISTICS OF DABIGATRAN AND VKA COHORTS IN NORTH AMERICA | |
Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study | |
Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation | |
A model to quantify the influence of treatment patterns and optimize outcomes in nAMD | |
Neovascular Age-Related Macular Degeneration A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect | |
Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference | |
Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: results from the LUMINOUS study | |
Real-world outcomes with ranibizumab in branch retinal vein occlusion: the prospective, global, LUMINOUS study | |
Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort | |
Treatment patterns and persistence rates with anti‐VEGF treatment for diabetic macular edema in the UK: a real‐world study | |
Wirkung des Neuropeptids Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) auf die glatte Muskulatur des Gastrointestinaltrakts von Meerschweinchen, Ratte und Mensch |